Open access peer-reviewed chapter

Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights

Written By

Om Parkash and Subha Saeed

Submitted: May 17th, 2017 Reviewed: October 3rd, 2017 Published: March 21st, 2018

DOI: 10.5772/intechopen.71405

Chapter metrics overview

1,476 Chapter Downloads

View Full Metrics


Nonalcoholic fatty liver disease (NAFLD) is characterized by a broad spectrum of clinical and histological presentations, ranging anywhere from simple steatosis to steatohepatitis. Of the patients with NAFLD, only a small fraction goes on to develop inflammation and fibrosis (i.e. NASH). Hence, understanding the underlying molecular mechanisms, which play part in progression of NAFLD and determine the disease severity, is extremely important. Almost two decades ago, Day and colleagues first described the “two-hit hypothesis” to explain progression of NAFLD. However, since then, the advances in field of molecular research have identified that NAFLD development and progression involves complex interplay of numerous determinants, including gut-derived signals, endoplasmic reticulum stress, adipose-derived adipokines, nutritional factors, hormonal imbalances and components of innate immunity which act in concert on genetically predisposed individuals to induce liver inflammation. This chapter reviews the different players of this “multiple-hit model”.


  • NASH
  • molecular basis
  • “multiple-hit model”
  • steatohepatitis

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of clinical and histo-pathological presentations, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the latter being characterized by inflammation, macrovesicular steatosis and apoptosis, with or without fibrosis. NAFLD can further progress to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [1]. The prevalence of NAFLD in Western countries ranges from 30–46% [2], whereas in Asian populations, it is about 15% [3]. About 30% of patients with NAFLD may have NASH [4].

Regarding progression of NASH to cirrhosis, estimated 10% of patients with NASH can progress to decompensated liver disease over 10 years and about 25% of patients develop cirrhosis over a span of 9 years [5]. It is very important to understand and uncover the underlying molecular mechanisms which explain the variable incidence and severity of steatohepatitis in only few patients with NAFLD, while most patients with steatosis never progress to steatohepatitis [6]. After Day and Colleagues first described “two-hit” model for pathogenesis of steatohepatitis in 1998, wherein steatosis (“first hit”) progresses to steatohepatitis due to rampant lipid peroxidation in liver (“second hit”) [7], recent advances in field of molecular research have identified numerous other culprits, collectively summed up in “multiple-hit” hypothesis [8]. The “multiple-hit” hypothesis examines multiple insults which act collectively and in-parallel on genetically predisposed individuals to induce development of NAFLD and expedite progression to further adverse pathologies. This chapter provides a review of literature for multiple culprits identified in development of NAFLD and NASH.


2. Development of hepatic steatosis

Several mechanisms are involved in development of hepatic steatosis [9, 10, 11], including increased fatty acid supply due to increased lipogenesis from both visceral and subcutaneous adipose tissue, increased dietary intake of fats, increased de novo hepatic lipogenesis, decreased free fatty acid oxidation, and decreased secretion of VLDL from liver. Increased free fatty acid delivery to liver and elevated de novo lipogenesis are major contributors to fatty acid accumulation in NAFLD.

Elevated hepatic de novo lipogenesis may be due to activation by transcription factors such as SREBP-1(activated by Insulin, regulated via Insulin Receptor Substrate (IRS) and maintains cellular cholesterol homeostasis), ChREBP (activated by glucose and increased hepatic de novo lipogenesis) and PPAR-γ. Studies have demonstrated that de novo lipogenesis in liver is elevated in insulin-resistant state and NAFLD [12, 13].

2.1. Lipoapoptosis: free fatty acids and cholesterol

Free fatty acid and Cholesterol are considered main players in lipotoxicity. Increased concentration of serum free fatty acids (16 Carbons and more; saturated or unsaturated) are seen in patients with NAFLD [14]. Apoptosis of hepatocytes, which is morphologic and pathologic feature of human NASH, is partly due to free fatty acids, as explained below.

Hepatocytes can undergo apoptosis via extrinsic pathway (activated by FAS ligand and tumor necrosis factor related apoptosis-inducing ligands) or intrinsic pathway (activated by intracellular stress of membrane-bound organelle, such as mitochondria, endoplasmic reticulum and mitochondria) [15]. Free fatty acids can induce apoptosis via following mechanisms, as demonstrated in Figure 1:

  • Mitochondrial pathway [16] (palmitic acid and stearic acid activate intrinsic apoptotic pathway via C-jun N-terminal kinase and Bim, leading to Bax activation, mitochondrial permeabilization, release of cytochrome c, and activation of Caspase 3 and 7),

  • Induction of Bim expression [17] (palmitic acid and stearic acid can activate transcription factor FoxO3a, which further induces expression of pro-apoptotic protein Bim),

  • Lysosomal pathway [18, 19]: Oleic acid and palmitic acid activate Bax which trans-locates to lysosomes, increases the permeability of lysosomes and causes release of cathepsin B, which further increase permeability of mitochondria and activates Caspases. Furthermore, Lysosomal permeabilization is also associated with activation of NF-κB, which results in generation of tumor necrosis factor-α (TNF-α) in hepatocytes,

  • Endoplasmic Reticulum [20]:Palmitic acid and stearic acid lead to activation of Endoplasmic reticulum (ER) stress pathway, which can lead to apoptosis, as explained later,

  • C-Jun N-Terminal Kinase: JNK belongs to family of intracellular mitogen-activated protein (MAP). The murine dietary models of obesity were associated with increased activation of JNK in liver [21]. JNK leads to activation of pro-apoptotic protein Bax [22] while it inactivates anti-apoptotic protein, Bcl-2 [23]

  • Death Receptors: Tumor Necrosis Factor Receptors, TNFR-1 and TNFR-2, and Fas are implicated in pathogenesis of steatohepatitis [24]. Obesity, being a chronic inflammatory state [25], is characterized by infiltration of adipose tissue by macrophages which release of inflammatory mediators, including TNF-α [26], with increased levels of TNF-α being observed in obesity. Upon activation by TNF-α, TNFR-1 activates NF-κB which leads to activation of pro-inflammatory genes and further apoptosis, if NF-κB mediated survival signals are inhibited. TNF-α can also lead to JNK activation, which can also lead to apoptosis if its activation is sustained [15].

    Fas is expressed on hepatocytes and upon binding by Fas ligand, it signals apoptotic cell death [15]. In dietary murine models, such as methionine and choline-deficient diet and high sucrose diet, steatosis is accompanied by increased expression of hepatic Fas [27], and increase in Fas expression confers increased Fas ligand-mediated apoptosis. Also, Monounsaturated fatty acid, oleic acid, under the transcriptional control of JNK, increases the expression of Fas and TRAIL-R2 on hepatocytes [15]. This is another mechanism by which fatty acids impart sensitivity to death receptor mediated extrinsic pathway of apoptosis,

  • Ceramide: Ceramides are composed of sphingosine and fatty acid, and availability of long chain fatty acids is a rate limiting step in synthesis of ceramide in ER [28]. In nutritional obesity with associated elevation of palmitic acid and stearic acid, excess synthesis of ceramide is possible. Palmitic acid and stearic acid-induced de novo ceramide synthesis in hematopoietic precursor cell line is associated with apoptosis. However, more studies are needed to highlight the exact contribution of ceramide to wide spectrum of NAFLD pathologies [29]

  • Toll-Like Receptors: toll-like receptors (TLR) are family of pattern recognition receptors that respond to microbial pathogens by activating innate arm of immune system [15]. Palmitic acid activates TLR4, leading to activation of NK-κB. This leads to upregulation of its target genes- i.e. TNF-α and Interleukin-6 (IL-6)- in macrophages and adipocytes [30]. When a high-fat diet is fed to mice lacking TLR4, there is a lack of inflammatory gene expression induction by high-fat diet, pointing towards the role of TLR4 in hepatic inflammation seen in NASH [31].

  • Oxidative Stress: Enhanced mitochondrial and microsomal fatty acid β oxidation and cytochrome P450 (CYP2E1) induction can lead to oxidative stress via generation of Reactive Oxygen species (ROS), as observed in human models of steatohepatitis [15, 32]. 4-hydroxy-2-noneal (HNE) and Thiobarbituric acid reacting substrate (TBARS), both markers of lipid peroxidation, are increased in patients with NAFLD and NASH [33, 34]. Thus, oxidative stress may contribute towards development of steatosis and steatohepatitis.

  • Long chain poly unsaturated fatty acids (LCPUFA): Oxidative stress leads to depletion of n-3 LCPUFA (e.g Eicosapentaenoic acid, EPA, and docosahexaenoic Acid, DHA) due to increased peroxidation or defective desaturation processes. Depletion of n-3 LCPUFA leads to upregulation of lipogenic and glycogenic effects from SREBP-1c and down-regulation of fatty acid oxidation effects from peroxisome proliferator activated receptor-α (PPAR-α), ultimately promoting hepatic steatosis [35]. In addition, depletion of LCPUFA can also lead to insulin resistance due to disturbance in membrane mediated processes such as insulin signaling [36]. From dietary prospective, a study aimed at assessing the influence of high-fat diet on Δ5 and Δ6 desaturase enzymes involved in LCPUFA formation, found that HFD lead to enhanced oxidative stress and macrovesicular steatosis, with diminution in desaturase activity and hence, depletion of LCPUFA [37].

Figure 1.

The figure demonstrates different mechanisms by which fatty acids impart lipotoxicity to hepatocytes (copyright © 2008 Georg Thieme Verlag KG) [15] (permission requested from Thieme publications).

The role of cholesterol in lipoapoptosis requires special mention. In an analysis conducted on human liver samples, subjects with NAFLD and NASH exhibited almost a 2-fold increase in free cholesterol, as compared to controls [38]. Furthermore, in a study to evaluate the effect of dietary free cholesterol loading in rodents, rats fed high cholesterol diet developed microvesicular steatosis and were sensitized to apoptotic effect of TNF-α, which may explain the lipoapoptosis due to cholesterol [39].

2.2. Triglycerides

Triglycerides are the main lipids stored in liver of patients with hepatic steatosis and recent studies suggest that triglycerides may in fact have protective functions. Diacylglycerol acyltransferase 1 and 2 (DGAT) catalyze final step in triglyceride synthesis. In a model of diet-induced obesity, mice with over-expression of DGAT1 in adipocytes and macrophages were protected from macrophage activation and accumulation in white adipose tissue, and from systemic inflammation and insulin resistance [9, 40]. In another study, DGAT2 antisense oligonucleotides lead to inhibition of triglycerides synthesis which improved liver steatosis but worsened liver damage, further strengthening the notion that liver triglycerides are protective in nature [41]. Thus, in summary, accumulation of triglycerides in liver might not actually be a pathology but in fact, an adaptive, beneficial response in situations where hepatocytes are exposed to toxic triglyceride metabolites and fatty acid excess due to increased caloric consumption [9, 42].

2.3. Inflammation leads to Steatosis or vice versa: chicken or the egg?

  • Treatment with anti-TNF antibody and metformin (an anti-diabetic drug that inhibits hepatic TNFα expression) in ob/ob mice (the laboratory model of nonalcoholic fatty liver disease) showed marked improvement in hepatic steatosis [43, 44].

  • In patients with alcoholic steatosis, treatment with anti-TNF antibody can improve hepatic steatosis [45].

  • Similarly, loss of Kupffer cells lead to decreased production of anti-inflammatory cytokine (IL-10), which lead to hepatic steatosis [46].

The above examples support the notion that Inflammation activates stress response in hepatocytes, which leads to lipid accumulation. In fact, hepatic steatosis may be considered a “bystander phenomenon” following inflammatory attacks. It may be a possibility that inflammation proceeds steatosis in NASH and, benign and non-progressive simple steatosis and NASH are different disease entities altogether [9].

2.4. Insulin resistance in NAFLD

NAFLD is strongly associated with hepatic and adipose tissue insulin resistance, as well as reduced whole body insulin sensitivity [47]. Different underlying molecular mechanisms have been identified which account for insulin resistance [8]:

  1. Serine phosphorylation of insulin receptor substrate (IRS) by inflammatory signals, such as c-jun N-terminal protein kinase 1 (JNK) or inhibitor of nuclear factor-jB kinase-b (IKKb) [48]

  2. Activation of nuclear factor kappa B (NF-κB) and Suppressors of cytokine signaling (SOCS) [49]

Insulin Resistance would mean that ability of Insulin to suppress lipolysis has been supressed, leading to increased delivery of free fatty acids to liver [50]. The free fatty acid can further exacerbate hepatic insulin resistance by causing translocation of PKC-γ isoform from cytosol to the membrane where it impairs hepatic insulin receptor substrate (IRS)-associated phosphatidylinositol activity [51].

2.4.1. Oxidative stress and insulin resistance

Prolonged excess oxidative load in steatosis, due to carbohydrates and lipids, leads to redox disequilibrium characterized by lower than normal hepatic anti-oxidative potential, for example, decreased hepatic glutathione (GSH) and reduced superoxide dismutase (SOD) activity, which further triggers insulin resistance (IR) [52]. This is validated by a data from study where increased reactive oxygen species (ROS) in 3T3-L1 cultured pre-adipocytes preceded the onset of Insulin resistance [53], by molecular mechanisms listed above. The insulin resistance due to exacerbated hepatic oxidative stress can in turn lead to upregulation of pro-oxidative CYP2E1 expression, the response which is normally attenuated by repressive effects of Insulin on CYP2E1 expression [54]. Thus, there is increasing evidence for positive reinforcement and interdependency between oxidative stress and insulin resistance in patients with Hepatic steatosis [52].

Thus, due to impairment in IRS activity and further down-regulation of IRS due to insulin resistance, SREBP is unregulated and over-expressed, leading to increased hepatic de novo lipogenesis [55]. Insulin Resistance, due to its ability to induce lipotoxicity, oxidative stress and inflammatory cascade, may be one of the “multiple hit” in pathogenesis of NAFLD and progression towards NASH [8, 56].


3. The gut-derived factors

The gut microbiota is implicated in the pathogenesis and progression of NAFLD, through so-called gut-liver axis [8]. A study aimed at analyzing human gut microbiome recognized different “enterotypes” [57] and “obese microbiome”, which has an ability to harvest increased amount of energy from diet, has been demonstrated in obese mice [58]. In fact, colonization of germ-free mice with “obese microbiome” leads to greater increase in total body fat as compared to colonization with “lean microbiome” [58]. The Figure 2 summarizes the role of gut-liver axis and adipose tissue in pathogenesis of NAFLD.

Figure 2.

The multiple parallel hits model. Lipotoxicity: (1) a liver loaded with lipids consisting primarily of trigylcerides might reflect a benign process because triglycerides might exert mostly protective effects. Furthermore, hyperleptinemia leads to oxidation of hepatic lipids, thereby also protecting this organ from lipotoxicity. When the capacity of peripheral and central organs of detoxifying “aggressive lipids” fails, lipotoxic attack of the liver might begin. Inflammation may precede steatosis in NASH. Gut-derived signals: Many signals beyond endotoxin might affect hepatic steatosis and inflammation. Several pathways have been identified how the gut microbiota might influence host energy metabolism: (2) Absence of the microbiota in germ-free mice correlates with increased activity of phosphorylated AMPK in the liver and the muscle (not shown). (3) Some of the breakdown products of polysaccharides are metabolized to SCFAs. SCFAs such as propionate and acetate are ligands for the G protein-coupled receptors Gpr41 and Gpr43. Shortage of SCFAs might allow the evolution of systemic inflammatory events. Such mechanisms elegantly combine diet, microbiota, and the epithelial cell as “nutrient sensor.” (4) The microbiota decreases epithelial expression of fasting-induced adipocyte factor (Fiaf), which functions as a circulating lipoprotein lipase (LPL) inhibitor and therefore is an important regulator of peripheral fat storage. (5) Several TLRs, such as TLR5 or TLR9, are not only able to affect microbiota but also to regulate metabolism, systemic inflammation, and insulin resistance, thus highlighting the role of the innate immune system in metabolic inflammation as observed in NASH. (6) Various nutrients such as trans fatty acids (TFAs), fructose or aryl hydrocarbon receptor (AhR) ligands such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) may directly lead to steatosis/liver inflammation. Adipose tissue-derived signals: Signals derived from the adipose tissue beyond toxic lipids might play a central role in NAFLD/NASH. (7) here, adipocytokines such as adiponectin and leptin, certain pro-inflammatory cytokines such as TNFα or IL-6, and others (the death receptor Fas, PPARγ) are of key relevance. The cytokine/adipocytokine milieu might be critical because ob/ob-adiponectin tg mice, although becoming severely obese, are not insulin-resistant. This suggests that in the hierarchy of processes soluble mediators play the central role. Adipose-derived mediators might indeed affect target organs such as the liver, because JNK1 adipose-deficient mice are protected from diet-induced obesity, and experiments have demonstrated that this effect is mediated mainly by IL-6 (a cytokine), which is of key importance in human obesity.” [9] (figure and associated caption used after permission from “John Wiley and Sons” [9]).

The liver receives more than 50% of its blood supply from splanchnic circulation [8], and hence, it is always exposed to gut-derived toxins. The ability of gut-derived factors like lipopolysaccharide (LPS) to flow in portal vein requires intestinal permeability, which in NAFLD is due to disrupted intercellular tight junctions in the intestine [59]. In Murine models of NAFLD, intestinal mucosa has bacterial overgrowth with increased intestinal permeability and concurrent reduction in expression of tight junction proteins [60]. Consequentially, plasma endotoxin levels are significantly high in patients with NAFLD and NASH [61], and high-fat diet is associated with 2–3 fold increase in plasma LPS levels [62]. LPS may act as a ligand for TLR with consequent activation of inflammatory cascade, including stress- and mitogen-activated protein kinases- JNK (explained later), p38, Interferon regulatory factors 3 and nuclear factor-jB – each having significant contribution towards insulin resistance, hepatic fat accumulation, obesity and NASH development and progression [63, 64]. Evidently, a continuous infusion of LPS for 4 weeks in mice mimicked high-fat diet phenotype, with noticeable increase in insulin resistance, increased liver triglyceride content and adipose tissue inflammation [62]. Similarly, the use of antibiotics reduced the intensity of inflammation in high-fat diet and ob/ob mice [65].

Another mechanism for gut microbiota to influence the host immune system is via their capacity to digest dietary fibers, such as resistant starch and nonstarch polysaccharide, to short chain fatty acids (SCFAs, mainly propionate, butyrate and acetate), which are absorbed by intestinal epithelium [66]. SCFAs, via their interactions with G protein-coupled receptor 43 (Gpr43), have anti-inflammatory function in various models of human ulcerative colitis [67, 68].

Enteric bacteria also suppress the synthesis of fasting-induced adipocyte factor (Fiaf), resulting in increased lipoprotein lipase activity and increased triglyceride accumulation in the liver [8, 9]. Gut microbiota also produce enzymes which cause the conversion of dietary choline to toxic compounds, particularly methylamines which, in the liver, are transformed to trimethylamine-N-oxide and induce inflammation and liver fibrosis [69]. Intestinal microbiome is a major source for production of hepatotoxic compounds such as alcohol, phenols and ammonia which are delivered to the liver by portal circulation. These compounds activate kupffer cells and stimulate the production of nitric oxide and other inflammatory cytokines [70]. Patients with NASH show abundance of alcohol-producing bacteria as compared to healthy children and children with simple steatosis [71]. This endogenous production of alcohol has a well-established role in generation of ROS and liver inflammation [72].

Furthermore, NLRP6 and NLRP3 inflammasomes, through their production of IL-18, play an important role in modulation of gut microbiota. In different mouse models, inflammasomes deficiency is associated with modifications in configuration of gut microbiota, and exacerbation of hepatic steatosis and inflammation. This is due to increased influx of TLR4 and TLR9 ligands into the portal circulation, leading to enhanced tumor necrosis factor-α (TNF-α) production in liver which leads to NASH progression [73].

3.1. Bile acids

The primary bile acids cholic acid and chenodeoxycholic acid are conjugated to glycine and taken up in distal ileum for transport to the liver [74]. By binding to cellular receptor farnesoid X receptor (FXR) in various organs of the body, bile acids act as signaling molecules to control overall metabolism of the host [75]. Upon activation of FXR by primary bile acids, downstream signals are generated which lead to inhibition of hepatic de novo lipogenesis, increased insulin sensitivity and protection of hepatocytes from bile acid-induced cytotoxicity [76]. However, the gut microbiota in distal ileum can deconjugate the bile acids and can further metabolize them to secondary bile acids, and thus, contribute towards obesity by altering lipid metabolism, through changes in bile acid pools and modulation of FXR signaling [74].

3.2. Dietary factors

The recent decades saw a dramatic increase in consumption of trans-fatty acids, and as evident from studies on mice, trans-fatty acids consumption leads to larger liver with NASH-like lesions and Insulin resistance [77]. Similarly, Fructose is a lipogenic, pro-inflammatory dietary factor associated with oxidative stress and upregulation of TNF-α [78], and daily fructose consumption is associated with liver inflammation and fibrosis [79]. Fructose diet can induce oxidative stress and hepatocellular damage by different mechanisms, including induction of protein fructosylation which activates SREBP and generates reactive oxygen species (ROS) [80]. Also fructose phosphorylation leads to depletion of ATP, which stimulates increased uric acid synthesis which in turn stimulates production of ROS [81]. Lastly fructose can induce mitochondrial disturbance which lead to disequilibrium between De novo Lipogenesis and VLDL, which promotes alteration of respiratory chain and uncoupling of oxidative phosphorylation with excess ROS production [82, 83].

Another receptor, aryl hydrocarbon receptor (AhR), is a ligand activated transcription factor which is activated by many constituents of our diet such as indolo-(3,2-b)-carbazole and 3,3′-diindolylmethane (metabolized from indole 2-carbinol), or flavonoids, and this pathway plays an important role in inflammation [84]. This is evident in transgenic mice with constitutively activated AhR as they develop spontaneous hepatic steatosis and increased hepatic oxidative stress [85].

Studies show that Low-Calorie, Low-carbohydrate soy-containing diet and Mediterranean diet rich in antioxidants and polyunsaturated fatty acids of n-3 series are known to be protective in reducing hepatic steatosis [86].


4. Adipose tissue-derived signal

Adipose tissue, with its ability to generate cytokines and adipocytokines, can be classified as a complex endocrine and immune organ which mediates different metabolic, immunological and inflammatory responses.

4.1. Adiponectin

Adiponectin is an anti-inflammatory cytokine with anti-lipogenic effects which protect non-adipocyte tissue, such as liver, from lipid accumulation [87]. Reduced levels of adiponectin are seen in conditions associated with development of NAFLD, namely obesity [88] and insulin resistance [89]. Hence, adiponectin levels are inversely related to visceral obesity and insulin resistance, and weight loss is an inducer of adiponectin synthesis [90]. The levels of adiponectin are significantly reduced in patients with NASH as compared to simple steatosis [91]. Thus adiponectin protects the liver against steatosis.

By activating cyclic-AMP dependent protein kinase (AMPK), adiponectin opposes fatty acid synthesis and promotes mitochondrial β-oxidation [92]. The anti-inflammatory effects of adiponectin are due to its ability to block activation of NF-κB which inhibits the release of pro-inflammatory cytokines such as TNFα and IL-6 [93]. The anti-inflammatory and hepatic lipid modulating effects of adiponectin may also be due to activation of peroxisome proliferator activated receptor-α (PPAR-α), as pharmacological treatment with PPAR-α agonist reverses experimental steatohepatitis [94]. Furthermore, PPAR-γ agonist, such as thiazolidinedione, stimulate adiponectin synthesis, and latter activates PPAR-α [95].

4.2. Leptin

Leptin is a gene product of ob gene and is produced by visceral adipocytes [96]. The levels of leptin directly correlate with body fat mass and adipocyte size [97]. Leptin has a potential dual action on NAFLD experimental models, exerting anti-steatotic, and pro-inflammatory/pro-fibrogenic actions [98]. In non-adipose tissue, such as liver, it prevents lipid accumulation by decreasing the expression of SREBP-1. Leptin exerts pro-fibrogenic effects by activating stellate cell in liver through hedgehock [99], mTOR [100] or kupffer cell-mediated TGF-β1 secretion which then activates stellate cell [101]. In mice models of NASH, gut-derived endotoxins can induce hyper-responsiveness to leptin, with subsequent upregulation of CD14 and accelerated fibrosis [102]. Experimental studies have demonstrated that leptin deficiency in mice may lead to hepatic steatosis which can be reversed by leptin replacement. On the other hand, excess leptin contributes towards hepatic inflammation and fibrosis [98]. It may be a possibility that anti-steatosis effects of leptin may predominate in initial stages of NAFLD while pro-inflammatory and pro-fibrotic effects might take over during disease progression phase [103]. However, the exact magnitude of contribution by Leptin towards NAFLD remains to be elucidated.

4.3. IL-6 and TNFα

In severe obesity, adipocytes are major source of IL-6 production, as evident by a study results where IL-6 expression was 100-fold elevated in adipose tissue as compared to liver in obese patients [9]. Similarly, elevated TNF-α production has been observed in cultures of peripheral blood cells collected from obese patients with NASH [104]. These two important pro-inflammatory cytokines are found to be elevated in obese patients and weight loss is associated with dramatic decrease in serum levels of these cytokines [105, 106].

The liver is the target organ for adipose tissue-derived 1 L-6 and TNFα. It is known that high-fat diet, also called “inflammatory diet”, stimulates JNK1 (mitogen-activated protein kinase, associated with apoptosis) signaling in adipocytes, which leads to IL-6 secretion by adipocytes. IL-6 further acts on hepatic cell, leading to hepatic steatosis and hepatic insulin resistance [48]. Continuous exposure to elevated levels of IL-6/TNF-α leads to many of the histological features of NASH such as hepatocyte necrosis and apoptosis, neutrophil chemotaxis and activation of hepatic stellate cells [107]. Also, they caused insulin resistance by upregulating hepatic suppressor of cytokine signaling 3 (SOCS3) [108].

Transcription factor nuclear factor-jB kinase b (NF-κB) and its IKK2 subunits is also important mediators of chronic inflammatory states. Persistent activation of NF-κB has been shown in animal models of NAFLD [109] and NASH [110].

4.4. Inflammasomes

Inflammasomes are large caspase-1 –activating multiprotein complexes that sense both endogenous and exogenous danger signals via intracellular NOD-like receptors (NLRs) [111]. Among the three prototypes of inflammasomes, NALP3 is associated with NAFLD and responds to danger signals by activating Caspase 1. Active Caspase-1 promotes cleavage and maturation of pro-inflammatory cytokines, such as IL-1β, IL-18, IL-33, which further promote inflammation [111]. Gut-derived endotoxin and free fatty acid may act as danger associated molecular pattern (DAMP) which may lead to activation of inflammasomes [112].

To validate the role of inflammasomes in NASH, it was seen that there was increased gene expression of inflammasomes in livers of patients with NASH as compared to liver of healthy controls [113]. Furthermore, LPS and saturated fatty acids amplify the expression and activation of inflammasomes, and free fatty acids sensitize the hepatocytes to LPS-induced IL-1β secretion [112]. It was seen observed that saturated fatty acids also directly induce hepatocyte apoptosis and activation of Caspase 8, which triggers the release of danger molecules from hepatocytes [112].

IL-1β induces the suppression of peroxisome proliferator activated receptor-α (PPAR-α), activates the stellate cells to promote fibrosis and promotes TNF-α-induced cell death [114].


5. Toll-like receptors and innate immunity

Toll-like receptors are sensors of microbial and endogenous danger signals which are expressed in innate immune cells and liver parenchyma and contribute towards progression of NASH [90]. Upon activation by gut microbiota-released pathogen- or damage- associated molecular pattern (PAMP and DAMP), downstream signals are activated which lead to progression of NASH. TLR2, TLR4 and TLR9 are most commonly associated with NASH [90].

The gut-derived bacterial endotoxin is brought to liver via portal circulation where they activate the kupffer cell by way of TLR4 receptor complex. This interaction leads to activation of nuclear transcription factors, leading to release of pro-inflammatory mediators such as TNFα which can induce liver injury and fibrosis [115]. The role of TLR4 in pathogenesis of NASH is further supported by study where TLR4-deficient mice, which were fed high fructose diet,were protected from formation of reactive oxygen species, induction of TNFα expression in liver and insulin resistance [116].

TLR9 is located on endoplasmic reticulum and is activated by unmethylated CpG DNA particles that are released from bacteria [90]. It is known that TLR9 is involved in steatohepatitis as TLR9-deficient mice are protected from liver inflammation [114]. In CDAA diet-(Choline-deficient amino acid defined diet) induced NASH, translocated bacterial DNA from gut binds to TLR9 receptor on kupffer cell to produce IL-1β which activate hepatic stellate cells to induce liver fibrosis, and also stimulate hepatocytes for lipid accumulation and cell death [114]. The induction of hepatic steatosis is independent of TLR2, however, functional TLR2 receptors are found on kupffer cells which mediate liver inflammation and fibrosis in CDAA diet-induced NASH [117].

Recently, another data that implicated TLR5 in pathogenesis of metabolic syndrome was presented. It was reported that mice deficient in TLR5 developed all features of metabolic syndrome including, hyperphagia, obesity, insulin resistance, pancreatic inflammation and hepatic steatosis. It was proposed that TLR5 altered the gut microbiota and the finding were reproducible when microbiota from TLR5 / mice was transferred to healthy mice [118]. However, another study did not find any such results in TLR5-deficient mice [119]. Indeed, more studies are needed to elicit role of TLR5 in steatohepatitis.


6. Endoplasmic reticulum (ER) stress

Endoplasmic reticulum (ER) is an important intracellular organelle involved in production, folding, post-translational modification and trafficking of secretory and membrane proteins. Also present in the ER is endoplasmic reticulum-associated degradation (ERAD) machinery that ensures that misfolded proteins are re-translocated back to cytoplasm for degradation by proteasomes [120]. Thus, ER serves as a quality control checkpoint, allowing only properly folded proteins to be transported to Golgi apparatus [121, 122] (Figure 3).

Figure 3.

The figure demonstrating the three different pathways of unfolded protein response [135] ( (

Any event that disturbs ER protein folding capacity- be it due to excessive protein synthesis, accumulation of misfolded proteins, depletion of calcium in ER, disturbance in redox regulation, glucose depletion, viral infection or high-fat diet (saturated fatty acid such as palmitic acid and stearic acid) [123] - leads to induction of evolutionarily conserved ER stress response, known as Unfolded protein response (UPR). The role of sensing ER stress and activating UPR is performed by three ER transmembrane proteins, mentioned as following:

  1. RNA-dependent Protein kinase-like ER eukaryotic initiation factor-2α Kinase (PERK)

  2. Inositol-requiring ER-to-nucleus signaling protein1 (IRE1) and,

  3. Transcription factor 6 (ATF6)

Each of these transmembrane proteins has an ER luminal domain to sense unfolded protein, a transfolded domain for targeting to the ER membrane, and a cytosolic domain to transmit signals to the transcriptional and/or translational apparatus [124]. In an unstressed cell, these ER proteins are maintained in an inactive state via their association with the ER chaperon protein, glucose-regulated protein 78 (GRP78)/Bip [125] and upon ER stress, unfolded/ misfolded proteins accumulation enhances the release of GRP78 from these stress-sensing proteins, leading to respective activation of PERK, ATF6 and IRE1 [126].

Upon activation, PERK, IRE1α and ATF6 induce signal transduction events that attenuate the accumulation of misfolded proteins in the ER by increasing expression of ER chaperons, inhibiting protein load on ER by decreasing mRNA translation, and stimulating retrograde transport of misfolded proteins from ER into cytosol for ubiquination and destruction by a process named ERAD [127]. However, under conditions where ER stress is chronically prolonged and the cell fails to restore homeostatsis in ER, the UPR will initiate cell apoptosis [126].

6.1. Protein kinase RNA-like endoplasmic reticulum kinase (PERK)

Activation of PERK leads to phosphorylation of α-subunit of eukaryotic Initiation Factor 2α (eIF-2α), leading to its inactivation and hence, attenuation of mRNA translation and decreased protein load on the ER [128]. The phosphorylated eIF-2α also causes preferential translation of UPR-dependent genes, such as activation transcription factor 4 (ATF 4). Further, ATF4 induces expression of several genes, including amino acid transporter, chaperons and CHOP [129] (“C/EBP homologous protein”, also known as ‘growth arrest and DNA damage (GADD 15)).

CHOP is an ER-derived transcription factor which is an important mediator of ER stress-induced apoptosis, as evident from studies where deletion of CHOP lead to attenuation of hepatocellular apoptosis in alcohol- and cholestasis-induced liver disease [130]. Apoptosis-relevant targets of the CHOP transcription factor include:

GADD34 [131]: promotes dephosphorylation of eIF2α,thus reversing translation inhibition. This leads to accumulation of unfolded proteins in ER compartment, and, simultaneously, permits translation of mRNA encoding pro-apoptotic genes,

DR5: a caspase activating cell-surface death receptor, and Ero 1 α (Endoplasmic Reticulum Oxidoreductase-1): hyperoxdises the ER and also activates the inositol triphosphate receptor (IP3R), causing excessive transport of Calcium from ER to the mitochondria and thus causing cell death) [132].

CHOP also induces apoptosis via direct inhibition of Bcl-2 transcription [133] and induction of Bim expression [134]. Bcl-2 proteins are localized within the ER membrane and are protective (anti-apoptotic) against ER stress. This cytoprotective function is mainly due to the ability of Bcl-2 to lower steady-state levels of ER Ca2+ via IP3Rs. The protective role of Bcl-2 in regulating ER Ca2+ can be inhibited by JNK-mediated phosphorylation of Bcl-2. The Phosphorylated Bcl-2 loses its anti-apoptotic function by being unable to bind pro-apoptotic “BH3-only” members of Bcl-2 family (i.e. Bim), leading to increasing calcium release from ER, which is associated with mitochondrial calcium uptake. This leads to increased mitochondrial permeabilization, release of cytochrome C, and hence apoptosis [127]. Calcium release from ER can also activate Caplains, which may further proteolytically activate Caspase-12 to induce apoptosis [135].

6.2. Inositol-requiring ER-to-nucleus signaling protein1 (IRE1)

Accumulation of unfolded proteins in ER leads to activation of IRE1, which further processes an intron from X-box binding protein-1 (XBP-1) mRNA and permits synthesis of XBP-1 protein. XBP-1 binds to promoters of genes involved in UPR (encoding ER chaperons) and ERAD to restore homeostasis and prevent cellular toxicity [127]. Apart from cytoprotective effects, IRE1 can also recruits inflammatory factors (JNK and NF-κB) which induce inflammatory response signaling [136], and apoptotic signal kinase-1 (ASK1) which causes downstream activation of stress kinases Jun-N-terminal Kinase (JNK) and p38 MAPK, that promotes apoptosis [137].

Activated JNK translocate to mitochondria and causes activation of Bim and Inhibition of Bcl-2. Activated JNK also induces the expression of pro-inflammatory genes by phosphorylating transcription factor activating protein-1(AP-1) [138]. Activated p38 MAPK phosphorylates and activates CHOP [127] to causes apoptosis.

6.3. Transcription factor 6 (ATF6)

ATF6 belongs to CREB family of transcription factors. Activation of ATF6 leads to its release from ER membrane, processing in the Golgi and entry into the nucleus. It trans-activates ER stress related genes such as ER chaperones, XBP-1, foldases and CHOP [124].

6.4. Endoplasmic reticulum stress and Steatosis

Hepatocytes, being rich in both smooth and rough EPR, perform diverse metabolic functions, including lipoprotein and very-low-density lipoprotein (VLDL) assembly and secretion, cholesterol biosynthesis and xenobiotic metabolism [121]. The Sterol regulatory element-binding protein (SREBPs) are key regulators of lipid homoeostasis and play crucial role in de novo lipogenesis [139], where SREBP-1 regulates fatty acid and triglycerides (TG) metabolism and SREBP-2 controls cholesterol metabolism and low density lipoprotein (LDL) receptor expression [140]. SREBP are transcription factors bound to ER membrane in inactive form and their activity is controlled within ER by interaction of SREBP-Cleavage Activating Protein (SCAP) and Insulin regulated proteins (Insigs). Insigs cause SREBP-SCAP complex to be retained within the ER and prevents SREBP-1 activation [141]. Under conditions of low sterols, Insigs are dissociated with SCAP, leading to migration of SREBP-SCAP complex to Golgi apparatus, where SREBP is processed to its active form by S1P and S2P [142]. Activated SREBP translocate to nucleus and regulates the various genes involved in lipid metabolism.

However, under ER Stress, rapid activation of precursor form of SREBP-1c and SREBP-1c target genes takes place, even in absence of Insulin [143]. Furthermore, ER stress induces proteolytic activation of SREBPs by increasing turnover of Insigs [142]. Hence, the recent data suggests that ER stress leads to hepatic steatosis by increasing de novo lipogenesis and upregulating the transcription of genes encoding for key lipogenic trans-activators and enzymes [121, 144].

Due to its high capacity for protein synthesis, ER stress plays an important part in mediating pathological changes in various liver diseases [135]. The signaling pathway activated by ER stress are implicated in lipotoxicity, Insulin Resistance, Inflammation and apoptotic cell death which are common to both NAFLD and NASH [123]. The presence of ER stress and activation of UPR in chronic disease (such as NAFLD) suggests that ability to resolve ER stress has been compromised. Inducing ER stress in individuals with genetically ablated eIF2α, IRE1α or ATF6α leads to hepatic steatosis [145], suggesting that steatosis results from impairment in the capacity to oxidize fatty acids and augmented by impaired lipoprotein secretion. Thus, initially UPR aims to prevent steatosis and re-establish ER homeostasis after ER stress but selective impairment to the UPR that reduce the ability of UPR to resolve ER stress leads to development and exacerbation of hepatic steatosis. However, further work is needed to investigate this Homeostatic Model hypothesis.

It is now well-established that various arms of UPR and its downstream signaling molecules play role in regulation of lipid metabolism and induction of various hepatic pathologies.

6.4.1. PERK-eIF2α-ATF4 pathway

The PERK-eIF2α-ATF4 pathway is reported to regulate lipogenesis and hepatic steatosis. PERK-dependent signaling has been crucial to sustained expression of lipogenic enzymes such as fatty acid synthase (FAS), ATP-citrate Lyase, and stearoyl-CoA Desaturase-1(SCD1) [146]. Phosphorylated eIF2α (activated form) is associated with enhanced expression of adipogenic nuclear receptor peroxisome proliferator activated receptor γ (PPAR γ) and its upstream regulators, and dephosphorylation of eIF2α using GADD34 leads to diminished hepatosteatosis in animals fed high-fat diet [147]. Furthermore, activated ATF4 increases expression of lipogenic genes, such as PPAR γ, sterol regulatory element-binding protein-1c (SREBP-1c), acetyl-CoA carboxylase (ACC), and FAS, in liver and white adipose tissue. Similarly, ATF4 knockout mice are protected from diet-induced hepatic steatosis [148, 149]. Thus, the current evidence suggests that PERK-eIF2α-ATF4 pathway plays an important role in promoting lipogenesis.

6.4.2. IRE1α-XBP1 pathway

The IRE1α-XBP1 pathway plays an important part in maintenance of hepatic lipid homeostatsis under ER stress and regulation of hepatic VLDL assembly and secretion [150]. IRE1α is also required for efficient synthesis of ApoB-containing lipoproteins [151]. Mice with hepatocyte specific deletion of IREIα show increased hepatic steatosis and reduced plasma lipids under ER stress condition due to altered expression of key metabolic players (such as PPARγ and C/EBPβ) and of enzymes involved in Triglycerides biosynthesis [151]. Thus, these results indicate IRE1α represses lipid accumulation in liver, especially under ER stress condition. However, the deletion of IRE1α leads to loss of this protective role of IRE1α, resulting in unresolved ER stress and hence, hepatic steatosis.

The role of XBP1 in lipogenesis is emphasized in a study where conditional disruption of XBP-1 in the liver of mice lead to reduced plasma level of triglycerides, cholesterol and free fatty acids, possibly due to decreased de novo lipogenesis [152]. XBP1 regulates lipogenesis in hepatocytes by directly binding to promotors of lipogenic genes such as SCD1 (Stearoyl-CoA Desaturase 1), DGAT2 (Diacylglycerol Transferase 2) and ACC2 (Acetyl-CoA carboxylase),thereby activating their transcription [152]. Thus under appropriate conditions, XBP1 promotes lipogenesis and contributes to hepatic lipogenesis.

6.4.3. Transcription factor 6 (ATF6)

ATF6 and SREBP are both ER membrane bound transcription factors, and nuclear ATF6 interacts with nuclear SREBP 2, antagonizing the SREBP2- regulated transcription of lipogenic genes and preventing lipid accumulation in cultures of liver cell [153]. Moreover, ATF2α-knockout mice develop hepatic steatosis in response to ER stress, due to reduced fatty acid oxidation and decreased VLDL secretion [154].

Thus, taken together, all three proximal UPR sensors including PERK, IRE1α and ATF6α, regulate lipid stores in liver but the degree to which the UPR contributes to hepatic steatosis may depend on activation of three proximal UPR sensors relative to each other, coupled with appropriate downstream protein–protein and/or protein-DNA interaction [120].

6.5. Endoplasmic reticulum stress and progression towards NASH

Multiple factors, including but not limited to, insulin action, oxidative stress, cytokine mediated signaling, inflammation, bacterial endotoxin, and excess fatty acids function in concert and interact with UPR to provoke disease progression of NAFLD towards NASH.

6.5.1. ER stress and hepatic inflammation

Several Signaling pathways connect ER stress to hepatic inflammation:

  • Reactive oxygen species (ROS)

    Protein folding in ER is intimately linked to generation of ROS, such that each disulfide bond formation during oxidative protein folding leads to production of 1 ROS [155]. An elevated protein folding load, as in ER stress, leads to accumulation of ROS, which may lead to inflammation. In turn, the oxidative stress from ROS can disrupt ER homeostasis and induce ER stress [156].

    However, in an unsurprising adaptive pathway, UPR activates an antioxidant program via transcription factor Nrf2 (nuclear factor erythroid-derived 2-related factor 2) to prevent accumulation of ROS [157]. Nrf2 is activated after phosphorylation by PERK pathway of UPR and it regulates the inducible expression of anti-oxidant response element-containing genes [157]. Importantly, Nrf2 deletion results in rapid onset and progression of steatohepatitis in mice provided a methionine choline-deficient (MCD) diet [158]. ATF4, one of the other terminal player of PERK pathway, has also been an important transcription factor in maintenance of adequate Glutathione levels in cells [159]. Thus, PERK arm of UPR and its downstream players are directly related to regulation of anti-oxidant effects. In a recent study, IRE1α-XBP1 branch of UPR was also found linked to anti-oxidant effect, where XBP1 deficiency leads to reduced catalase expression [160].

  • NF-κB and JNK

    In response to ER stress, IRE1α binds to adaptor protein tumor-necrosis factor α (TNF-α) receptor-associated factor 2 (TRAF2). IRE1α-TRAF2 complex activates NF-κB and JNK, both of which induce production of Pro-inflammatory cytokines, such as C-reactive protein (CRP), amyloid P-component, fibrinogen, and interleukin-6 (IL-6) [161].

    The UPR-mediated signaling can lead to activation of NF-κB not only via IRE1α but also via PERK [162] and/or ATF6 pathway [163]. Activation of NF-κB has been detected in steatohepatitis induced by MCD diet, however, the exact mechanism about how ER stress-induced signaling involving NK-κB and JNK might regulate inflammation, cell survival and apoptosis in NAFLD is still unknown.

  • PKR (double-stranded RNA-activated Protein Kinase)

    PKR is an interferon-induced Serine/threonine protein kinase, activated by dsRNA, and is capable of activating NF-κB and eIF2α in response to dsRNA and oxidative stress, respectively [164]. PKR activity is increased in adipose tissue and liver of murine model of obesity [165]. With its ability to respond to pathogens, nutrients and organelle stress, PKR appears to be core component of inflammatory and immune pathways. However, depending on which key factor is activated downstream, that is, either NF-κB (pro-apoptotic) or eIF2α (anti-apoptotic), PKR may “serve as molecular clock to time the sequential events of survival and death” [166]. In summary, PKR affirms the complexity of UPR signaling and its downstream outcomes [120].


    CREBH is a transcription factor belonging to CREB/ATF family of transcription factor and is required for liver synthesis of Amyloid P-component and CRP [167]. CREBH is activated via RIP process (Regulated Intramembrane Proteolysis: release and transport of ER resident protein from the ER membrane to Golgi for processing) upon ER stress. Other than ER stress, TNFα, Interleukin 6 (IL6) and lipoprotein LPS also induce expression of CREBH [168]. This makes room for another revelation: ER stress in the liver may be linked to systemic inflammation via the RIP- mediated mobilization of CREBH [120].

6.5.2. ER stress and apoptosis

Apoptosis is an important component of disease progression in NAFLD [169] and is positively correlated with disease severity in NASH [24]. The failure of UPR in mitigating the ER stress leads to cell death via several mechanisms (Figure 4).

Figure 4.

Different mechanisms for ER stress-induced apoptosis [135] ( (

CHOP is one of the best characterized UPR-regulated pro-apoptotic protein [120]. CHOP is an ER-derived transcription factor activated downstream from PKR- and ATF6-pathway of UPR. Significance of CHOP in inducing apoptosis can be emphasized from results of study where silencing CHOP lead to decreased hepatocyte apoptosis in alcohol-induced liver disease [130] and attenuated cholestasis-induced liver fibrosis [170]. However, the role of CHOP is paradoxical in NAFLD, as demonstrated in study where CHOP deletion can reduce palmitate-induced apoptosis in hepatocyte cell line, whereas MCD diet-induced apoptosis was not reduced in CHOP knockout mice [171, 172].

CHOP has been described as an unstable protein compared to other protein chaperons like GRP78 [120]. Above described paradoxical role of CHOP in NAFLD makes way for observation: role of CHOP as a pro-apoptotic protein may be dependent on level of CHOP expression, the presence of factors which increase stability and/or protein–protein interactions that direct cell specific effects [173, 174]. Hence, future studies regarding role of CHOP in mice model are needed to elicit exact contributions of CHOP towards disease progression in NAFLD and NASH.

Furthermore, The IRE1 branch of the UPR, via its activation of JNK and Caspase 12 [175], and its interaction with Bax and Bak (two pro-apoptotic Bcl2 family members) [176], can also activate path towards apoptosis.

Additionally, another mechanism proposed for hepatic cell apoptosis is dysregulation in ER calcium flux. The ER calcium flux is regulated by ER stress, ER-localized protein and BCL-2 proteins interacting with other ER-localized proteins [177, 178]. The ERO1α-mediated activation of IP3, as mentioned earlier, can lead to disruption of ER calcium homeostasis [132]. This disruption inhibits sarco-endoplasmic reticulum Ca2+-ATPase uptake pump, decreasing the folding capacity of ER, and hence, can induce ER stress and apoptosis [179]. Truncated variants of sarco-endoplasmic reticulum Ca2+-ATPase have also been implicated in dysregulation of Calcium flux [180]. Subsequently, the release of ER calcium and its uptake in mitochondria leads to mitochondrial membrane permeabilization, and activation of intrinsic apoptotic pathway. Recent studies also suggest that Smooth and Rough ER may be physically and functionally interacting with mitochondria via tethers and reduction in lengths of these tethers in response to pro-apoptotic agents might be one mechanism for apoptosis [181, 182].


7. Genetic factors

A possible explanation for observed inter-individual variability in susceptibility to NAFLD and progressive NASH is provided by genetics. Patatin-like phospholipase domain-containing 3 (PNPLA3), also called adiponutrin, is a protein expressed on endoplasmic reticulum, and on lipid droplets in hepatocytes and adipocytes [183]. It is activated after feeding and is the master regulator of lipogenesis by SREBP-1c. The 148 M variant of PNPLA3 is associated with increased expression of lipogenic transcription factor SREBP1c and alters the lipid catabolism [184]. The 148 M variant is associated with increased severity of NAFLD. In another study, patients with 148 M variant in genotype developed increased steatosis, with augmented lobular inflammation, hepatocellular ballooning and NASH [185].

7.1. Epigenetic modifications

Epigenetic modifications, mainly including microRNA, DNA methylation, histone modification and ubiquination, refers to phenotypic changes irrespective of changes to underlying DNA. “miRNA” are small single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes [186]. The miR-122, which accounts for 70% of all miRNA in the liver, is significantly under-expressed in NASH subjects compared to normal subjects [187]. Inhibition of miR-122 via antisense oligonucleotide in diet-induced obesity mouse models resulted in decreased mRNA expression of acetyl-CoA carboxylase-2, fatty acid synthase, SREBP1c, Stearoyl-CoA desaturase, all of which are key lipogenic factors in human NASH, and the histology showed marked improvement in liver steatosis [188]. In another study in mice, the plasma cholesterol level, hepatic fatty acid and cholesterol synthesis rate as well as HMG CoA reductase level were all significantly reduced after silencing miR-122 [189]. These findings strongly suggest the significance miR-122 in the regulation of lipid metabolism. Besides miR-122, miR-34a and miR-146b were shown to be significantly over-expressed in human NASH [187].

Similarly, aberrant methylation patterns of genomic DNA have been linked to NAFLD. A recent study found positive correlation between NAFLD and hepatic DNA methylation of GpC in PPAR-δ and mitochondrial transcription factor A (TFAM), with methylation being higher in NAFLD liver as compared to control [190]. In conclusion, genetic and epigenetic factors interact with other determinants to produce NAFLD phenotype and determine the rate of its progression [187].


8. Conclusion

The above laborious and detailed discussion on complex molecular mechanisms associated with disease progression in NAFLD does point towards the fact: The pathogenesis and progression of disease in NAFLD is complex interplay of different hormonal, immunological, metabolic, genetic and environmental components. Each component can act on its own or act in concert with other culprits to causes augmented damage to liver. However, more studies are needed to uncover the still unknown players, and to understand the interactions between the different players of multiple-hit model.



ACCacetyl-CoA carboxylase
AhRaryl hydrocarbon receptor
AMPKcyclin AMP dependent protein kinase
AP-1activating protein-1
ASK1apoptotic signal kinase-1
ATF6activating transcription factor 6
CDAA dietcholine-deficient, amino acid defined diet
CHOPCCAAT-enhancer-binding protein homologous protein
ChREBPcarbohydrate response element-binding protein
CREBcAMP response element-binding protein
DAMPdanger associated molecular pattern
DGATdiacylglycerol transferase
DR5death receptor 5
eIF-2αeukaryotic initiation factor-2α
ERendoplasmic reticulum
Ero 1 αendoplasmic reticulum oxidoreductase 1
Fiaffasting-induced adipocyte factor
FXRfarnesoid X receptor
GADDgrowth arrest and DNA damage
IKKbInhibitor of nuclear factor kappa-B kinase subunit beta
Insigsinsulin regulated proteins
IRE 1inositol-requiring ER-to-nucleus signaling protein1
IRSinsulin receptor substrate
JNKJun N-terminal Kinase
MAPmitogen-activated protein
MAPKmitogen-activated protein kinase
mTORmechanistic target of rapamycin
NAFLDnonalcoholic fatty liver disease
NALPNACHT, LRR and PYD domains-containing protein 3
NF-κBnuclear factor κ beta
NLRnod-like receptor
NLRPNLR family, pyrin domain-containing 3 inflammasomes
Nrf2nuclear factor-erythroid-derived 2-related factor 2
PERKprotein kinase RNA- like endoplasmic reticulum kinase
PKC-γprotein kinase C-gamma
PKRRNA activated protein kinase
PNPLA3patatin-like phospholipase domain-containing 3
PPARperoxisome proliferator activated receptor
ROSreactive oxygen species
SCAPSREBP-cleavage activating proteins
SCD1stearoyl-CoA desaturase-1
SCFAshort chain fatty acid
SOCSsuppressor of cytokine signaling
SREBPsterol regulatory element-binding protein
TBARSthiobarbituric acid reacting substrate
TFAMmitochondrial transcription factor A
TGF-β1transforming growth factor-β1
TLRtoll-like receptor
TNFtumor necrosis factor
TNFRtumor necrosis factor receptor
TRAILTNF-related apoptosis-inducing ligand
UPRunfolded protein response
XBP1X-box binding protein-1


  1. 1. AS Y, Keeffe EB. Nonalcoholic fatty liver disease. Reviews in Gastroenterological Disorders. 2002;2(1):11-19
  2. 2. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):274-285
  3. 3. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. Journal of Hepatology. 2008;48(Suppl 1):S104-S112
  4. 4. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clinics in Liver Disease. 2010;14(4):591-604
  5. 5. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md). 2006;44(4):865, 73
  6. 6. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology (Baltimore, Md). 1995;22(6):1714, 9
  7. 7. Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842-845
  8. 8. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, Clinical and Experimental. 2016;65(8):1038-1048
  9. 9. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology (Baltimore, Md). 2010;52(5):1836-1846
  10. 10. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):424-431
  11. 11. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of Clinical Investigation. 2005;115(5):1343-1351
  12. 12. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. The American Journal of Clinical Nutrition. 2003;77(1):43-50
  13. 13. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726-735
  14. 14. Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Digestive Diseases and Sciences. 2001;46(11):2347-2352
  15. 15. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in Liver Disease. 2008;28(4):360-369
  16. 16. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. The Journal of Biological Chemistry. 2006;281(17):12093-12101
  17. 17. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, Gores GJ. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. The Journal of Biological Chemistry. 2007;282(37):27141-27154
  18. 18. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene. 2004;23(16):2881-2890
  19. 19. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (Baltimore, Md). 2004;40(1):185-194
  20. 20. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. American Journal of Physiology. Endocrinology and Metabolism. 2006;291(2):E275-E281
  21. 21. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-336
  22. 22. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. The Journal of Biological Chemistry. 2006;281(30):21256-21265
  23. 23. Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, et al. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World Journal of Gastroenterology. 2016;22(8):2512-2523
  24. 24. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437-443
  25. 25. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation. 2003;112(12):1796-1808
  26. 26. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995;95(5):2409-2415
  27. 27. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. Journal of Hepatology. 2003;39(6):978-983
  28. 28. Mari M, Fernandez-Checa JC. Sphingolipid signalling and liver diseases. Liver international : official journal of the International Association for the Study of the Liver. 2007;27(4):440-450
  29. 29. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. The Journal of Biological Chemistry. 1997;272(6):3324-3329
  30. 30. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(10):2062-2068
  31. 31. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of Clinical Investigation. 2006;116(11):3015-3025
  32. 32. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology. 2004;99(8):1497-1502
  33. 33. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatology Research: The Official Journal of the Japan Society of Hepatology. 2005;33(2):132-134
  34. 34. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. The American Journal of Gastroenterology. 2005;100(4):850-855
  35. 35. Valenzuela R, Videla LA. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food & Function. 2011;2(11):644-648
  36. 36. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. The Journal of Nutritional Biochemistry. 2006;17(1):1-13
  37. 37. Valenzuela R, Barrera C, Espinosa A, Llanos P, Orellana P, Videla LA. Reduction in the desaturation capacity of the liver in mice subjected to high fat diet: Relation to LCPUFA depletion in liver and extrahepatic tissues. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 2015;98:7-14
  38. 38. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2007;46(4):1081-1090
  39. 39. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metabolism. 2006;4(3):185-198
  40. 40. Koliwad SK, Streeper RS, Monetti M, Cornelissen I, Chan L, Terayama K, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. The Journal of Clinical Investigation. 2010;120(3):756-767
  41. 41. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md). 2007;45(6):1366-1374
  42. 42. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: A roadmap to lipotoxicity. Trends in Endocrinology and Metabolism: TEM. 2010;21(6):345-352
  43. 43. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Medicine. 2000;6(9):998-1003
  44. 44. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2003;37(2):343-350
  45. 45. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. Journal of Hepatology. 2003;38(4):419-425
  46. 46. Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA. Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochimica et Biophysica Acta. 2009;1792(11):1062-1072
  47. 47. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia. 2005;48(4):634-642
  48. 48. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science (New York, N.Y.). 2008;322(5907):1539-1543
  49. 49. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nature Reviews. Molecular Cell Biology. 2006;7(2):85-96
  50. 50. Luyckx F, Lefebvre P, Scheen A. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss. Diabetes & Metabolism. 2000;26(2):98-106
  51. 51. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. American Journal of Physiology-Endocrinology and Metabolism. 2003;284(5):E863-EE73
  52. 52. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends in Molecular Medicine. 2006;12(12):555-558
  53. 53. Houstis N, Rosen E, Lander E. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944-948. Find this article online
  54. 54. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology. 2002;35(2):263-273
  55. 55. Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocrine Reviews. 2008;29(7):939-960
  56. 56. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: Beyond steatosis and inflammation. International Journal of Molecular Sciences. 2014;15(5):8591-8638
  57. 57. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-180
  58. 58. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1131
  59. 59. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2009;49(6):1877-1887
  60. 60. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2007;292(2):G518-GG25
  61. 61. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-1481
  62. 62. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772
  63. 63. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends in Microbiology. 2004;12(12):562-568
  64. 64. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Journal of Hepatology. 2007;47(4):571-579
  65. 65. Pappo I, Becovier H, Berry EM, Freund HR. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. The Journal of Surgical Research. 1991;51(2):106-112
  66. 66. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: Roles of resistant starch and nonstarch polysaccharides. Physiological Reviews. 2001; 81(3):1031-1064
  67. 67. Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Valpiani D, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Alimentary Pharmacology & Therapeutics. 1995;9(3):309-313
  68. 68. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282-1286
  69. 69. Zeisel SH, Wishnok JS, Blusztajn J. Formation of methylamines from ingested choline and lecithin. The Journal of Pharmacology and Experimental Therapeutics. 1983;225(2):320-324
  70. 70. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology. 2010;7(12):691-701
  71. 71. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology (Baltimore, Md). 2013;57(2):601-609
  72. 72. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. Journal of Hepatology. 1999;30(6):1155-1159
  73. 73. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-185
  74. 74. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242-249
  75. 75. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731-744
  76. 76. Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes & Metabolism. 2008;34(6):685-691
  77. 77. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;295(5):G987-G995
  78. 78. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. Journal of Hepatology. 2008;48(6):983-992
  79. 79. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1961-1971
  80. 80. Lim JS, Mietus-Snyder M, Valente A, Schwarz J-M, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature Reviews. Gastroenterology & Hepatology. 2010;7(5):251-264
  81. 81. Lanaspa MA, Sanchez-Lozada LG, Choi Y-J, Cicerchi C, Kanbay M, Roncal-Jimenez CA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress potential role in fructose-dependent and-independent fatty liver. The Journal of Biological Chemistry. 2012;287(48):40732-40744
  82. 82. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999-1007
  83. 83. Jegatheesan P, De Bandt JP. Fructose and NAFLD: The multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230
  84. 84. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: A perspective on potential roles in the immune system. Immunology. 2009;127(3):299-311
  85. 85. Lee JH, Wada T, Febbraio M, He J, Matsubara T, Lee MJ, et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology. 2010;139(2):653-663
  86. 86. Hernandez-Rodas MC, Valenzuela R, Videla LA. Relevant aspects of nutritional and dietary interventions in non-alcoholic fatty liver disease. International Journal of Molecular Sciences. 2015;16(10):25168-25198
  87. 87. Xu A. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. Journal of Clinical Investigation. 2003;112(1):91-100
  88. 88. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications. 1999;257(1):79-83
  89. 89. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. The Journal of Clinical Endocrinology and Metabolism. 2001;86(5):1930-1935
  90. 90. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). International Journal of Molecular Sciences. 2013;14(10):20704-20728
  91. 91. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54(1):117-121
  92. 92. Yamauchi T, Kamon J, Minokoshi YA, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine. 2002;8(11):1288-1295
  93. 93. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006;6(10):772-783
  94. 94. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769
  95. 95. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094-2099
  96. 96. Friedman JM, Leibel R, Siegel D, Walsh J, Bahary N. Molecular mapping of the mouse ob mutation. Genomics. 1991;11(4):1054-1062
  97. 97. Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie. 2012;94(10):2082-2088
  98. 98. Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism, Clinical and Experimental. 2015;64(1):60-78
  99. 99. Choi SS, Syn W-K, Karaca GF, Omenetti A, Moylan CA, Witek RP, et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. The Journal of Biological Chemistry. 2010;285(47):36551-36560
  100. 100. Aleffi S, Navari N, Delogu W, Galastri S, Novo E, Rombouts K, et al. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2011;301(2):G210-G2G9
  101. 101. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology. 2009;137(2):713-723. e1
  102. 102. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metabolism. 2012;16(1):44-54
  103. 103. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating Leptin in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Springer; 2016
  104. 104. Poniachik J, Csendes A, Díaz JC, Rojas J, Burdiles P, Maluenda F, Videla LA. Increased production of IL-1α and TNF-α in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Santiago, Chile: Cytokine; 2006;33(5): 252-257
  105. 105. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science (New York, N.Y.). 1993;259(5091):87-91
  106. 106. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. The Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1154-1159
  107. 107. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55(3):415-424
  108. 108. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. The Journal of Biological Chemistry. 2003;278(16):13740-13746
  109. 109. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nature Medicine. 2005;11(2):183-190
  110. 110. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients. The American Journal of Gastroenterology. 2004;99(9):1708-1717
  111. 111. Yu HB, Finlay BB. The caspase-1 inflammasome: A pilot of innate immune responses. Cell Host & Microbe. 2008;4(3):198-208
  112. 112. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology (Baltimore, Md). 2011;54(1):133-144
  113. 113. Wree A, McGeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. Journal of Molecular Medicine. 2014;92(10):1069-1082
  114. 114. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139(1):323-334. e7
  115. 115. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Experimental Biology and Medicine. 2003;228(8):882-890
  116. 116. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology (Baltimore, Md). 2009;50(4):1094-1104
  117. 117. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology (Baltimore, Md). 2013;57(2):577-589
  118. 118. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science (New York, N.Y.). 2010;328(5975):228-231
  119. 119. Letran SE, Lee S-J, Atif SM, Flores-Langarica A, Uematsu S, Akira S, et al. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. The Journal of Immunology. 2011;186(9):5406-5412
  120. 120. Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxidants & Redox Signaling. 2011;15(2):505-521
  121. 121. Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radical Research. 2015;49(12):1405-1418
  122. 122. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutation Research. 2005;569(1-2):29-63
  123. 123. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (New York, N.Y.). 2004;306(5695):457-461
  124. 124. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the unfolded protein response. Cell Death and Differentiation. 2006;13(3):374-384
  125. 125. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008;454(7203):455-462
  126. 126. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology. 2007;8(7):519-529
  127. 127. Sano R, Reed JCER. Stress-induced cell death mechanisms. Biochimica et Biophysica Acta. 2013;1833(12):3460-3470
  128. 128. Sozen E, Ozer NK. Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: An updated mini-review. Redox Biology. 2017;12:456-461
  129. 129. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular Cell. 2003;11(3):619-633
  130. 130. Ji C, Mehrian-Shai R, Chan C, Hsu YH, Kaplowitz N. Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcoholism, Clinical and Experimental Research. 2005;29(8):1496-1503
  131. 131. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. The Journal of Cell Biology. 2001;153(5):1011-1022
  132. 132. Li G, Mongillo M, Chin KT, Harding H, Ron D, Marks AR, et al. Role of ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. The Journal of Cell Biology. 2009;186(6):783-792
  133. 133. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Molecular and Cellular Biology. 2001;21(4):1249-1259
  134. 134. Wang XZ, Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science (New York, N.Y.). 1996;272(5266):1347-1349
  135. 135. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. Journal of Hepatology. 2011;54(4):795-809
  136. 136. Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Molecular and Cellular Biology. 2006;26(8):3071-3084
  137. 137. Ron D, Hubbard SR. How IRE1 reacts to ER stress. Cell. 2008;132(1):24-26
  138. 138. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239-252
  139. 139. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, et al. Transcriptional activities of nuclear SREBP-1a, −1c, and −2 to different target promoters of lipogenic and cholesterogenic genes. The Journal of Lipid Research. 2002;43(8):1220-1235
  140. 140. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-340
  141. 141. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 2002;110(4):489-500
  142. 142. Lee JN, Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. The Journal of Biological Chemistry. 2004;279(43):45257-45265
  143. 143. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. The Journal of Clinical Investigation. 2009;119(5):1201-1215
  144. 144. Lee JS, Zheng Z, Mendez R, Ha SW, Xie Y, Zhang K. Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. Toxicology Letters. 2012;211(1):29-38
  145. 145. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Developmental Cell. 2008;15(6):829-840
  146. 146. Bobrovnikova-Marjon E, Hatzivassiliou G, Grigoriadou C, Romero M, Cavener DR, Thompson CB, et al. PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(42):16314-16319
  147. 147. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metabolism. 2008;7(6):520-532
  148. 148. Seo J, Fortuno ES 3rd, Suh JM, Stenesen D, Tang W, Parks EJ, et al. Atf4 regulates obesity, glucose homeostasis, and energy expenditure. Diabetes. 2009;58(11):2565-2573
  149. 149. Xiao G, Zhang T, Yu S, Lee S, Calabuig-Navarro V, Yamauchi J, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. The Journal of Biological Chemistry. 2013;288(35):25350-25361
  150. 150. Wang S, Chen Z, Lam V, Han J, Hassler J, Finck BN, et al. IRE1alpha-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. Cell Metabolism. 2012;16(4):473-486
  151. 151. Zhang K, Wang S, Malhotra J, Hassler JR, Back SH, Wang G, et al. The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis. The EMBO Journal. 2011;30(7):1357-1375
  152. 152. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science (New York, N.Y.). 2008;320(5882):1492-1496
  153. 153. Zeng L, Lu M, Mori K, Luo S, Lee AS, Zhu Y, et al. ATF6 modulates SREBP2-mediated lipogenesis. The EMBO Journal. 2004;23(4):950-958
  154. 154. Yamamoto K, Takahara K, Oyadomari S, Okada T, Sato T, Harada A, et al. Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress. Molecular Biology of the Cell. 2010;21(17):2975-2986
  155. 155. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: Roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxidants & Redox Signaling. 2009;11(10):2409-2427
  156. 156. Hanada S, Harada M, Kumemura H, Bishr Omary M, Koga H, Kawaguchi T, et al. Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. Journal of Hepatology. 2007;47(1):93-102
  157. 157. Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway. The International Journal of Biochemistry & Cell Biology. 2006;38(3):317-332
  158. 158. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, et al. Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2010;298(2):G283-G294
  159. 159. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and Cellular Biology. 2003;23(20):7198-7209
  160. 160. Liu Y, Adachi M, Zhao S, Hareyama M, Koong AC, Luo D, et al. Preventing oxidative stress: A new role for XBP1. Cell Death and Differentiation. 2009;16(6):847-857
  161. 161. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (New York, N.Y.). 2000;287(5453):664-666
  162. 162. Jiang H-Y, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR, et al. Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. Molecular and Cellular Biology. 2003;23(16):5651-5663
  163. 163. Yamazaki H, Hiramatsu N, Hayakawa K, Tagawa Y, Okamura M, Ogata R, et al. Activation of the Akt-NF-κB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. The Journal of Immunology. 2009;183(2):1480-1487
  164. 164. Donze O, Abbas-Terki T, Picard D. The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. The EMBO Journal. 2001;20(14):3771-3780
  165. 165. Nakamura T, Furuhashi M, Li P, Cao H, Tuncman G, Sonenberg N, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell. 2010;140(3):338-348
  166. 166. Donze O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N. The protein kinase PKR: A molecular clock that sequentially activates survival and death programs. The EMBO Journal. 2004;23(3):564-571
  167. 167. Luebke-Wheeler J, Zhang K, Battle M, Si-Tayeb K, Garrison W, Chhinder S, et al. Hepatocyte nuclear factor 4alpha is implicated in endoplasmic reticulum stress-induced acute phase response by regulating expression of cyclic adenosine monophosphate responsive element binding protein H. Hepatology (Baltimore, Md). 2008;48(4):1242-1250
  168. 168. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell. 2006;124(3):587-599
  169. 169. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2006;44(1):27-33
  170. 170. Tamaki N, Hatano E, Taura K, Tada M, Kodama Y, Nitta T, et al. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294(2):G498-G505
  171. 171. Pfaffenbach KT, Gentile CL, Nivala AM, Wang D, Wei Y, Pagliassotti MJ. Linking endoplasmic reticulum stress to cell death in hepatocytes: Roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. American Journal of Physiology - Endocrinology and Metabolism. 2010;298(5):E1027-E1E35
  172. 172. Zhang XQ, CF X, CH Y, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(7):1768-1776
  173. 173. Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biology. 2006;4(11):e374
  174. 174. Masciarelli S, Fra AM, Pengo N, Bertolotti M, Cenci S, Fagioli C, et al. CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Molecular Immunology. 2010;47(6):1356-1365
  175. 175. Yoneda T, Imaizumi K, Oono K, Yui D, Gomi F, Katayama T, et al. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. The Journal of Biological Chemistry. 2001;276(17):13935-13940
  176. 176. Hetz C, Bernasconi P, Fisher J, Lee A-H, Bassik MC, Antonsson B, et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1α. Science (New York, N.Y.). 2006;312(5773):572-576
  177. 177. Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(1):105-110
  178. 178. Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene. 2008;27(3):285-299
  179. 179. Luciani DS, Gwiazda KS, T-LB Y, Kalynyak TB, Bychkivska Y, Frey MH, et al. Roles of IP 3 R and RyR Ca 2+ channels in endoplasmic reticulum stress and β-cell death. Diabetes. 2009;58(2):422-432
  180. 180. Chami M, Oulès B, Szabadkai G, Tacine R, Rizzuto R, Paterlini-Bréchot P. Role of SERCA1 truncated isoform in the proapoptotic calcium transfer from ER to mitochondria during ER stress. Molecular Cell. 2008;32(5):641-651
  181. 181. Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. The Journal of Cell Biology. 2006;174(7):915-921
  182. 182. Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, et al. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science (New York, N.Y.). 1998;280(5370):1763-1766
  183. 183. Huang Y, He S, Li JZ, Seo Y-K, Osborne TF, Cohen JC, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences. 2010;107(17):7892-7897
  184. 184. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. The Journal of Biological Chemistry. 2010;285(9):6706-6715
  185. 185. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2010;52(4):1274-1280
  186. 186. Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World journal of gastroenterology: WJG. 2012;18(45):6546
  187. 187. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48(6):1810-1820
  188. 188. Esau C, Davis S, Murray SF, XX Y, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism. 2006;3(2):87-98
  189. 189. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs. Nature. 2005;438(7068):685-689
  190. 190. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez Gianotti T, Castano GO, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology (Baltimore, Md). 2010;52(6):1992-2000

Written By

Om Parkash and Subha Saeed

Submitted: May 17th, 2017 Reviewed: October 3rd, 2017 Published: March 21st, 2018